TMPRSS-13 (Recombinant)
- Expression system
- HEK293
- Cat. #
- REC-TMPRSS13
In stock
- SKU
- REC-TMPRSS13
Target Overview
TMPRSS-13 (UniProt Q9BYE2; gene TMPRSS13) is a type II transmembrane serine protease belonging to the mosaic serine protease subgroup of the TTSP family. The full-length human protein spans 586 amino acids and is anchored at the cell membrane, with its catalytic serine protease domain oriented extracellularly. This recombinant form is produced in HEK293 cells, a mammalian expression system that supports the native disulfide bonding and glycosylation patterns characteristic of TTSP-family ectodomains — properties important for physiologically relevant enzymatic activity in vitro. Documented substrates include the proform of PRSS8/prostasin, which TMPRSS-13 cleaves to generate active prostasin, and the proform of hepatocyte growth factor (HGF), activation of which promotes downstream MAPK signaling. These cleavage events place TMPRSS-13 at biologically significant nodes in epithelial homeostasis and growth factor processing. Researchers use this recombinant in fluorogenic peptide-substrate activity assays to confirm and characterise catalytic function, and in inhibitor screening formats to determine IC50 values for candidate serine protease inhibitors — including peptidomimetics and small molecules under investigation as broad-spectrum host-directed antivirals. The protein is also used as a positive-control antigen in Western blot and immunohistochemistry antibody validation workflows. Researchers requiring a validated antibody matched to this recombinant can pair SKU REC-TMPRSS13 with the Triple Point Biologics TMPRSS-13 antibody (RP-TMPRSS13), which has been validated for Western blot against human target. Predicted cross-reactivity with monkey and pan-species orthologs provides additional flexibility for comparative studies.
Background
Applications
- Fluorogenic peptide-substrate activity assay to confirm catalytic serine protease function
- Inhibitor IC50 determination in small-molecule and peptidomimetic TTSP-family selectivity panels
- Prostasin (PRSS8) zymogen cleavage assay to characterise substrate activation kinetics
- HGF precursor cleavage assay coupled with downstream MAPK signaling readouts
- Western blot positive-control antigen for validation of anti-TMPRSS-13 antibodies (pairs with RP-TMPRSS13)
- IHC standard for antibody titration and specificity confirmation in human tissue sections
- Broad-spectrum antiviral host-protease inhibitor profiling panel component
- Biophysical characterisation (thermal shift, SPR) of inhibitor or substrate binding to the TMPRSS-13 ectodomain
References
- Banas V et al. Towards broad-spectrum antiviral drugs: inhibition of transmembrane serine proteases. Biochem J. 2026. doi:10.1042/BCJ20250335. PMID: 41847980.
- Végh B et al. Efficient production of fully active, SARS-CoV-2-priming, wildtype TMPRSS2 ectodomain via co-expression of HAI-2 allows for both auto- and cross-activation mechanisms. Biochem J. 2025. doi:10.1042/BCJ20253453. PMID: 41408854.
- Wang Y et al. TMEM106B Supports Viral Entry and Syncytia Formation Mediated by the Spike Proteins From Omicron BA.2.86 and JN.1. J Med Virol. 2025. doi:10.1002/jmv.70439. PMID: 40556423.
- Fraser BJ et al. Structural basis of TMPRSS11D specificity and autocleavage activation. Nat Commun. 2025. doi:10.1038/s41467-025-59677-3. PMID: 40348740.
- Lemieux G et al. From N-0385 to N-0920: Unveiling a Host-Directed Protease Inhibitor with Picomolar Antiviral Efficacy against Prevalent SARS-CoV-2 Variants. J Med Chem. 2025. doi:10.1021/acs.jmedchem.4c02468. PMID: 40163818.
Additional Specifications
| Storage Buffer | 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol |
|---|---|
| Endotoxin Level | <0.1 EU/µg by LAL |
| Purity (%) | >90% by SDS-PAGE |
| Expression System | HEK293 |
| Subcellular Localization | Type II transmembrane serine protease; cell surface |
Frequently Asked Questions
What is the expected molecular weight of recombinant TMPRSS-13 on SDS-PAGE or Western blot?
The full-length human TMPRSS-13 protein (UniProt Q9BYE2) has a predicted molecular weight of ~66 kDa based on its 586-amino-acid sequence. Due to N-linked glycosylation introduced during HEK293 expression — which mirrors the native glycosylation pattern of the TTSP ectodomain — the apparent MW on reducing SDS-PAGE typically runs between 70–80 kDa. If you are running non-reducing conditions, disulfide-stabilized conformers may shift the band further. Always compare against a prestained ladder calibrated in the 50–100 kDa range.
What processing or isoform state is this TMPRSS-13 recombinant — zymogen or activated form?
This recombinant is produced as the catalytically active ectodomain of TMPRSS-13, encompassing the serine protease domain. TMPRSS-13 belongs to the mosaic serine protease subgroup of the TTSP family and undergoes autocatalytic or trans-activation cleavage at a conserved Arg/Lys site in the activation loop. The HEK293 expression system supports the disulfide bonding required for proper domain folding; however, the precise zymogen-to-active ratio in the final lot is confirmed by activity assay before release. A certificate of activity is available on request.
What substrates does TMPRSS-13 cleave and which fluorogenic peptide substrate should I use in a activity assay?
TMPRSS-13 documented biological substrates include the proform of PRSS8/prostasin and the proform of HGF — both cleaved at basic residue motifs. For in vitro fluorogenic assays, Boc-Gln-Ala-Arg-AMC and Tos-Gly-Pro-Arg-AMC are suitable trypsin-like serine protease substrates and have been used with closely related TTSPs. Start at 100–200 µM substrate concentration with 0.5–2 µg/mL recombinant TMPRSS-13 in assay buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl). Monitor AMC release at Ex 360 nm / Em 460 nm. Titrate enzyme concentration to keep initial velocity in the linear range.
What is the recommended assay buffer and pH for TMPRSS-13 protease activity in vitro?
The storage buffer — 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol — serves as a practical starting point for activity assays. TMPRSS-13 is a serine protease with preference for basic residues (Arg/Lys at P1), and its activity is generally optimal near physiological pH (7.4–8.0). Avoid EDTA, which is not required for this serine protease but is non-inhibitory; standard serine protease inhibitors (PMSF, AEBSF, benzamidine) must be excluded from assay buffers. BSA (0.01–0.1%) can be added to reduce non-specific surface adsorption in low-enzyme-concentration experiments.
How do I determine a starting concentration of TMPRSS-13 recombinant for an IC50 inhibitor screening experiment?
For IC50 measurements, the enzyme concentration should be well below the Ki of the tightest inhibitor you intend to rank — typically 0.5–2 nM total active enzyme — to avoid tight-binding artefacts (Cheng-Prusoff applies). Convert the supplied protein concentration (µg/mL) to molar using the apparent MW of ~70–75 kDa. Run a substrate titration (Km determination) first using the Boc-Gln-Ala-Arg-AMC or equivalent substrate, then set substrate at ~Km for IC50 experiments. This ensures the measured IC50 is easily corrected to Ki using the standard competitive inhibition equation.
Can I use REC-TMPRSS13 as a positive control antigen on Western blot with the matched TPB antibody RP-TMPRSS13?
Yes — this is one of the primary intended uses of the pairing. REC-TMPRSS13 and the rabbit polyclonal antibody RP-TMPRSS13 are produced and validated in the same laboratory, guaranteeing epitope compatibility. Load 20–50 ng of REC-TMPRSS13 per lane on a 10% SDS-PAGE gel under reducing conditions; RP-TMPRSS13 should detect the ~70–80 kDa glycosylated band cleanly. This positive control is especially useful when validating antibody lot-to-lot consistency or when setting up TMPRSS-13 detection in a new cell lysate panel. See the RP-TMPRSS13 product page (/anti-tmprss-13-rabbit-polyclonal-antibody) for recommended dilutions.
How much recombinant TMPRSS-13 should I load as a Western blot positive control to get a clean band?
20–50 ng per lane is the recommended starting range when using RP-TMPRSS13 at standard working dilutions. At 20 ng you should obtain a detectable band without saturating the signal; 50 ng provides a robust reference band suitable for molecular weight confirmation alongside cell lysates. Use reducing SDS-PAGE sample buffer; boiling for 5 min at 95°C is appropriate. The glycosylated band will appear at approximately 70–80 kDa. If running alongside high-protein-content tissue lysates, load the recombinant in a dedicated lane rather than mixing, to avoid signal interference.
How should I store and handle REC-TMPRSS13 to preserve enzymatic activity — can I refreeze unused protein?
REC-TMPRSS13 is supplied in 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol in single-use aliquots and should be stored at -20°C. Repeated freeze-thaw cycles measurably reduce serine protease activity — even one additional cycle can result in 20–30% activity loss in our experience with TTSP-family ectodomains. Thaw each aliquot on ice, use what you need, and discard the remainder rather than refreezing. If you anticipate multiple uses within a week, a working aliquot may be kept at 4°C for up to 5–7 days; add BSA to 0.1 mg/mL to stabilize dilute preparations.
Validation imagery coming soon
Western blot validation figures for REC-TMPRSS13 will be published here as they are produced in-house.
If you would like to see existing validation data for this antibody before publication, request a sample copy.